Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies. Fortrea has extensive experience ...

The growth is driven by pharma and biotech companies outsourcing clinical trials to specialized providers. Since late-stage trials are larger and more complex, they are more frequently outsourced ...

“We are excited to partner with SCRS to launch and support this working group,” said Mike Clay, senior vice president of Global Project Delivery at Fortrea. “Clinical trials are becoming ...

Spun off from Labcorp in 2023, Fortrea Holdings (NASDAQ:FTRE) provides contract research and development services for pharmaceutical and biotechnology companies, specializing in clinical trials ...

Called Evinova, the new unit has emerged with alliances already in place with contract research organisations Parexel and Fortrea ... and planning of new clinical trials, drawing on artificial ...

The global US Clinical Trial Services Market is expected to reach US$39.61 billion by 2030 from US$25.57 billion in 2025, at ...

and Fortrea is there. The clinical research industry needs to evolve. Success will depend on our ability to be both agile and disciplined, more flexible in how we design and execute trials ...

Fortrea shares last traded at $11.49, with a volume of 1,761,855 shares changing hands. The company reported $0.18 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.18).

What is the current share price of Fortrea Holdings (FTRE)? Fortrea Holdings's (FTRE) current share price is $9.67. This constitutes a price movement of 9.50% when compared to the share price 7 days ...